First Phosphate Corp CEO John Passalacqua joined Steve Darling from Proactive to share details of a key hire as Garry Siskos has been tabbed as the company’s COO and CFO.

Passalacqua told Proactive Siskos brings with him a wealth of experience with 25 years of international experience including work with two of Canada’s Top 100 growth organizations. Cisco sees great potential in First Phosphate, particularly in the automotive sector and the emerging EV and battery storage markets. He appreciates the company's sustainable and green approach to mining, positioning them as a world-class opportunity.

#proactiveinvestors #firstphosphatecorp #phosphate #BéginLamarcheproject #CEOInterview #CompanyUpdate #StrategicGrowth #SustainableMining #GreenApproach #EVMarket #BatteryStorage #WorldClassOpportunity #LFPBattery #MiningIndustry #CorporateUpdate #Milestones2023 #PilotFacilities #PhosphateConcentrate #IronSulfate #IronPowder #InvestmentOpportunity #FutureOfMining #LeadershipTeam #CEOandCFO #BusinessExpansion #CorporateStrategy

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at Proactive's London studio to talk about the latest news on the specialty biopharmaceutical company's p140 platform.

Immupharma recently announced that the US Food and Drug Administration (FDA) has endorsed the company's proposal for a late-stage clinical trial for the treatment of chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disorder.

McCarthy says he's "looking forward with quiet confidence" to getting the next response from the FDA, about its lupus indication.

#ProactiveInvestors #IMM #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #biopharma

Proactive research analyst Daniel Appiah speaks to Thomas Warner after publishing a research note on Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF), entitled "Phase 1 approval for lead chronic pain drug."

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) CEO Clarissa Sowemimo-Coker recently told Proactive's Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, represents a significant milestone for the company.

#ProactiveInvestors #OCTP #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

HANetf's iClima Earth co-founder and CEO Gabriela Herculano speaks to Proactive's Thomas Warner following the release of the latest edition of the monthly report, titled "A Monthly Dose of Climate Solutions."

This month's report evaluates the mixed fortunes of green stocks, asking "are we wrong or are we early?" and Herculano makes her case for the latter.

#ProactiveInvestors #iclima #climate #climatechange #greentechnology #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Benchmark Holdings PLC (AIM:BMK) Trond Wiliksen and Septima Maguire speak to Proactive's Thomas Warner after the aquaculture biotechnology company released both its interim and second quarter results.

Wiliksen describes the business as being "on track" while Maguire provides a more detailed breakdown of progress towards its medium-term goals.

#ProactiveInvestors #BMK #Benchmark #aquaculture #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Maximus Resources Ltd (ASX:MXR) MD Tim Wither tells Proactive the company will shortly begin follow-up drilling after intercepting up to 1.3% nickel at the Misho prospect, confirming the presence of a fertile nickel sulphide-bearing komatiite channel near the Kambalda district in Western Australia. Eight reverse circulation (RC) holes were recently completed to test for sulphide mineralisation, with four shallow holes intersecting visible disseminated sulphides of pyrrhotite and pentlandite with concentrations ranging from 1-5%.

#ProactiveInvestors #MaximusResources #ASX #nickel

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Lithium Energy Ltd (ASX:LEL) chairman William Johnson discusses with Proactive the positive outcomes from metallurgical tests on the Burke Graphite Project in Queensland. Results confirm the feasibility of upgrading Burke graphite to battery-grade material, with graphite concentrate grades exceeding 96% Total Graphitic Carbon (TGC) using standard flotation processes. The company is now progressing with a PFS to produce battery anode material.

#ProactiveInvestors #LithiumEnergyLtd #ASX #Graphite #BatteryMetals

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Technology Metals Australia Ltd (ASX:TMT) MD Ian Prentice speaks with Proactive following news the company has secured firm commitments for an $11.5 million capital raise. The placement garnered strong support from existing and new strategic and institutional investors, including cornerstone shareholder Resource Capital Fund VII L.P. (RCF VII).

#ProactiveInvestors #TechnologyMetalsAustralia #ASX #Vanadium #BatteryMetals

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

QMines Ltd (ASX:QML) MD Andrew Sparke tells Proactive the company is honing in on high-grade copper in azurite- and malachite-bearing structures at its cornerstone Mt Chalmers Copper-Gold Project in central Queensland. Ground truthing over an electromagnetic target led the explorer to strong base metal anomalism, with early-stage pXRF analysis returning up to 30.04% copper in gossans and 23.48% in quartz breccia.

#ProactiveInvestors #QMinesLtd #ASX #MtChalmers #Copper

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Island Pharmaceuticals Ltd (ASX:ILA) CEO David Foster speaks with Proactive soon after receiving Investigational New Drug (IND) clearance and the lifting of a clinical hold for its lead ISLA-101 clinical program from the US Food and Drug Administration (FDA). ISLA-101 is being repurposed for the prevention and treatment of dengue fever and other mosquito borne diseases. The company is moving rapidly into clinical trials for dengue-infected patients.

#ProactiveInvestors #IslandPharmaceuticals #ASX #DengueFever #biotech

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews